Connect Biopharma Holdings Ltd
Connect Biopharma Holdings Ltd is a clinical-stage biopharmaceutical company focused on developing rademikibart, an antibody designed to target IL-4Rα for asthma and COPD. The company is headquartered in San Diego and has no commercial product revenue yet, relying on clinical progress, licensing, and collaboration economics to fund development.
Tilikausi 2025 · muutos edellisvuodesta
Kehitys 2020–2025
Liiketoiminta
Osuus liikevaihdostaRademikibart is the company's core antibody program being advanced for asthma and COPD.
Internal R&D work covering discovery, preclinical studies, and clinical trials.
Milestones and reimbursements from the Simcere partnership in Greater China.
Filing, prosecution, and maintenance of patents and marketing approvals.
Asiakkaat
Connect Biopharma does not sell a marketed drug directly to end customers today; its economic counterparties are collaboration partners, regulators, and eventually physicians and patients if rademikibart is approved. The current revenue base comes from Simcere under the China license agreement, while the long-term commercial customer base would be healthcare providers and payers in asthma and COPD markets.
Simcere licenses rademikibart for Greater China and pays milestones, reimbursements, and future royalties.
Health agencies review clinical, safety, and manufacturing data needed for approval and commercialization.
Future end users of rademikibart if the drug is approved and commercialized.
Pulmonologists and treating clinicians would adopt the therapy based on efficacy and safety data.
Insurers and health systems would influence uptake through reimbursement and formulary access.
Strategia
The company’s strategy is to advance rademikibart through clinical development while using partnerships to extend reach and monetize the asset before full internal commercialization. Near term, the focus is on generating clinical data in asthma and COPD, supporting regulatory filings, and converting the China collaboration into milestone and royalty value.
Clinical readouts are the main value driver for a clinical-stage biotech with no product sales.
China NDA progress can trigger milestones and future royalties while validating the asset.
The company is pre-commercial and depends on existing cash and external financing.
Exclusive rights and patent protection are central to future partnering and commercialization value.
Maantiede
The company is headquartered in San Diego, California, but its most explicit commercial exposure is Greater China through the Simcere license. Its reported development and collaboration activity also spans the U.S. and China, making the business dependent on cross-border regulatory, IP, and data-security conditions.
Riskit
Connect Biopharma faces the typical risks of a clinical-stage biotech: trial failure, regulatory delays, and the possibility that rademikibart never reaches commercial scale. It also has meaningful China-related exposure through its Simcere partnership, plus IP, data-security, and financing risks that can materially affect value creation and dilution.
- Clinical development failureVaikutus: KriittinenTodennäköisyys: Matala
Rademikibart is still in development, so negative efficacy or safety data could eliminate the main value driver.
Kohdistuu: Phase 2 asthma and COPD programs
- Regulatory approval riskVaikutus: KorkeaTodennäköisyys: Matala
Approval timing and outcomes depend on regulators in the U.S. and China, and delays can defer commercialization and milestones.
Kohdistuu: NDA review and future marketing approvals
- China partner execution riskVaikutus: Korkea
The company relies on Simcere to develop, manufacture, and commercialize rademikibart in Greater China.
Kohdistuu: Greater China license agreement
- Financing and dilution riskVaikutus: Korkea
The company is loss-making and expects to fund operations through equity, debt, or collaborations.
Kohdistuu: Future capital raises
- Intellectual property and data-security riskVaikutus: KeskitasoTodennäköisyys: Kohtalainen
Biotech value depends on patent protection and secure handling of proprietary and patient data.
Kohdistuu
Kirjanpito
Harkinnanvaraiset erätUpfront license fees, milestones, and reimbursements are recognized based on contract terms and performance obligations.
Vaikutus: Can cause large swings in quarterly revenue, as seen in the Simcere agreement.
Clinical trial and manufacturing costs are estimated before invoices are finalized.
Vaikutus: Affects operating expense timing and reported losses.
Equity awards are a recurring non-cash expense for a development-stage biotech.
Vaikutus: Raises reported R&D and G&A expense without immediate cash outflow.
Cash preservation depends on the valuation and maturity of invested funds.
Vaikutus: Influences liquidity presentation and interest-related income.
Samankaltaisia listattuja yhtiöitä
Julkisesti listattuja yhtiöitä, joilla on samankaltainen liiketoiminta.
LakeShore Biopharma Co., Ltd.
LSBCF · Pharmaceutical Preparations
Impact BioMedical, Inc
IBO · Pharmaceutical Preparations
Arbutus Biopharma Corp
ABUS · Pharmaceutical Preparations
Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious disease, with its current development efforts centered on chronic hepatitis B.
Propanc Biopharma, Inc.
PPCB · Pharmaceutical Preparations
Cue Biopharma, Inc.
CUE · Pharmaceutical Preparations
Cue Biopharma is a clinical-stage biopharmaceutical company developing injectable precision immunotherapies designed to selectively modulate disease-relevant T cells.
Immix Biopharma, Inc.
IMMX · Pharmaceutical Preparations
Päivitetty: 24.9.2026